Viewing StudyNCT04751383



Ignite Creation Date: 2024-05-06 @ 3:47 PM
Last Modification Date: 2024-10-26 @ 1:56 PM
Study NCT ID: NCT04751383
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-07-11
First Post: 2021-02-11

Brief Title: Testing the Combination of Two Immunotherapy Drugs Magrolimab and Dinutuximab in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
Sponsor:
Organization: National Cancer Institute NCI

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 82
Enrollment Type: ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE1
Observational Models:
Time Perspective List:
Who Masked List: